OKYO Pharma Ltd ADR (NASDAQ:OKYO) — Market Cap & Net Worth
Market Cap & Net Worth: OKYO Pharma Ltd ADR (OKYO)
OKYO Pharma Ltd ADR (NASDAQ:OKYO) has a market capitalization of $59.80 Million ($59.80 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21275 globally and #4709 in its home market, demonstrating a -3.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OKYO Pharma Ltd ADR's stock price $1.59 by its total outstanding shares 37610676 (37.61 Million). Review OKYO Pharma Ltd ADR (OKYO) total liabilities to assess the company's total debt and financial obligations.
OKYO Pharma Ltd ADR Market Cap History: 2022 to 2026
OKYO Pharma Ltd ADR's market capitalization history from 2022 to 2026. Data shows change from $71.84 Million to $59.05 Million (-18.86% CAGR).
Index Memberships
OKYO Pharma Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #612 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2045 of 3165 |
Weight: OKYO Pharma Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OKYO Pharma Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OKYO Pharma Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OKYO by Market Capitalization
Companies near OKYO Pharma Ltd ADR in the global market cap rankings as of June 19, 2026.
Key companies related to OKYO Pharma Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
OKYO Pharma Ltd ADR Historical Marketcap From 2022 to 2026
Between 2022 and today, OKYO Pharma Ltd ADR's market cap moved from $71.84 Million to $ 59.05 Million, with a yearly change of -18.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $59.05 Million | -24.15% |
| 2025 | $77.85 Million | +80.02% |
| 2024 | $43.25 Million | -35.03% |
| 2023 | $66.57 Million | -7.33% |
| 2022 | $71.84 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of OKYO Pharma Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.80 Million USD |
| MoneyControl | $59.80 Million USD |
| MarketWatch | $59.80 Million USD |
| marketcap.company | $59.80 Million USD |
| Reuters | $59.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more